BRIEF-U.S. FDA panel recommends label change for Takeda's diabetes drug

April 14 (Reuters) - An advisory panel to the U.S. Food and Drug Administration voted 13-3 that Takeda Pharmaceutical's diabetes drug Nesina should contain information about a potential increased risk of heart failure.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.